Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study.
J Comp Eff Res · 2023
Last updated 2026-05-28In a study of teenagers with obesity, those given semaglutide experienced a 17% reduction in BMI and lost an average of 18 kg more than those given a placebo. More participants in the semaglutide group achieved weight loss of 5%, 10%, 15%, or 20% or more compared to the placebo group. The medication was generally well tolerated, with serious side effects being uncommon.
AI summary of the abstract below.
| Journal | J Comp Eff Res, 2023 |
|---|---|
| Citations | 8 |
| Relative citation ratio | 0.93 |
| NIH percentile | 48 |
| Molecules | semaglutide |
| Conditions studied | Obesity |
Abstract
What is this summary about? This is a plain language summary of the STEP TEENS research study, which was originally published in the . As more teenagers are living with obesity than ever before, researchers are searching for new treatments. This was the first study looking at how well the medicine semaglutide works as a treatment for obesity in teenagers. What were the results? In this study, researchers looked at the effect of semaglutide on body mass index (BMI) and weight loss compared to a dummy medicine (placebo). A 17% decrease in BMI was reported for teenagers treated with semaglutide compared with placebo. For weight loss, an 18 kg decrease was seen when comparing semaglutide with placebo. Researchers found that there were more teenagers who had weight loss of 5%, 10%, 15%, and 20% or more in the group given semaglutide compared with the group given placebo. Improvements were also seen with semaglutide treatment for some risk factors for other diseases caused by obesity. Semaglutide was generally well tolerated by the teenagers with obesity in this study, and serious medication side effects did not happen very often. What do the results mean? The results from this study showed that there were no safety issues with semaglutide in teenagers with obesity, and that semaglutide can be used to help them lose weight. : NCT04102189 (ClinicalTrials.gov).
Verbatim abstract via PubMed 36534451 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.